205 related articles for article (PubMed ID: 3423522)
1. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
Cremer P; Vekemans M
Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
[No Abstract] [Full Text] [Related]
2. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
[TBL] [Abstract][Full Text] [Related]
3. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
Bilotta P; Favilli S
Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
[No Abstract] [Full Text] [Related]
5. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
6. [Side effects of oral contraceptives in the first treatment cycle].
Feichtinger W; Babor P; Herczeg KM; Heyda M; Hoffmann R; Plöckinger B; Steinhauser B
Wien Med Wochenschr; 1991; 141(18-19):412-5. PubMed ID: 1837965
[TBL] [Abstract][Full Text] [Related]
7. Clinical studies with a new, low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol.
Acta Obstet Gynecol Scand Suppl; 1987; 144():1-44. PubMed ID: 2964165
[No Abstract] [Full Text] [Related]
8. Use of an oral contraceptive containing drospirenone in an extended regimen.
Sillem M; Schneidereit R; Heithecker R; Mueck AO
Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial.
Brill K; Then A; Beisiegel U; Jene A; Wünsch C; Leidenberger F
Contraception; 1996 Nov; 54(5):291-7. PubMed ID: 8934063
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of a low-dose contraceptive--Femodene].
Rachev E; Damianov L; Dukovski A; Katsarova M
Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
[TBL] [Abstract][Full Text] [Related]
11. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives according to the normophasic principle.
Borglin NE; Klottrup P
Arzneimittelforschung; 1978; 28(12):2354-7. PubMed ID: 582954
[TBL] [Abstract][Full Text] [Related]
13. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
[No Abstract] [Full Text] [Related]
14. Cycle control, safety and acceptability of a new oral contraceptive containing ethinylestradiol 15 micrograms and gestodene 60 micrograms.
Jaithitivit L; Jaisamrarn U; Taneepanichskul S
J Med Assoc Thai; 2012 May; 95(5):630-5. PubMed ID: 22994020
[TBL] [Abstract][Full Text] [Related]
15. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
[TBL] [Abstract][Full Text] [Related]
16. Toward a new concept of "natural balance" in oral estroprogestin contraception.
Chabbert-Buffet N; Gerris J; Jamin C; Lello S; Lete I; Lobo P; Nappi RE; Pintiaux A
Gynecol Endocrinol; 2013 Oct; 29(10):891-6. PubMed ID: 23931030
[TBL] [Abstract][Full Text] [Related]
17. Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo.
Loncar D; Milosević-Djordjević O; Zivanović A; Grujicić D; Arsenijević S
Contraception; 2004 Apr; 69(4):327-31. PubMed ID: 15033409
[TBL] [Abstract][Full Text] [Related]
18. [Oral contraceptives: 30 vs 20 micrograms of ethinyl estradiol (EE)].
Urdinola J
Adv Contracept; 1994 Jul; 10 Suppl 1():41-9. PubMed ID: 7839871
[No Abstract] [Full Text] [Related]
19. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm].
Milchev N; Terzhumanov R; Grozdanov G; Krumov G
Akush Ginekol (Sofiia); 1992; 31(2):42-3. PubMed ID: 1342561
[No Abstract] [Full Text] [Related]
20. [The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene].
Lech MM; Swiatek EJ
Ginekol Pol; 2004 Mar; 75(3):209-14. PubMed ID: 15181879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
